Polypharmacy in chronic liver disease patients: Implications for disease severity, drug-drug interaction, and quality of life

被引:2
|
作者
Farooq, Juveriya [1 ,2 ]
Sana, M. M.
Chetana, P. M. [1 ]
Almuqbil, Mansour [3 ]
Bhat, Nagapati Prabhakar [2 ]
Sultana, Rokeya [4 ]
Khaiser, UmaimaFarheen [5 ]
Asdaq, Syed Mohammed Basheeruddin [6 ]
Almalki, Mutlaq Eidhah M. [7 ]
Khormi, Amro Mohammed Sawadi [6 ,7 ]
Albraiki, Salem Ahmad [8 ]
Almadani, Moneer E. [9 ]
机构
[1] Shree Devi Coll Pharm, Dept Pharm Practice, Mangalore 574142, Karnataka, India
[2] Yenepoya Deemed Univ, Dept Pharmacol, Deralakatte 575018, Karnataka, India
[3] King Saud Univ, Coll Pharm, Dept Clin Pharm, Riyadh 11451, Saudi Arabia
[4] Yenepoya Deemed Univ, Yenepoya Pharm Coll & Res Ctr, Dept Pharmacognosy, Deralakatte 575018, Karnataka, India
[5] Yenepoya Deemed Univ, Yenepoya Pharm Coll & Res Ctr, Dept Pharm Practice, Deralakatte 575018, Karnataka, India
[6] AlMaarefa Univ, Coll Pharm, Dept Pharm Practice, Riyadh 13713, Saudi Arabia
[7] King Saud Univ Med City, Riyadh, Saudi Arabia
[8] King Abdul Aziz Med City, Dept Pharm, Riyadh, Saudi Arabia
[9] AlMaarefa Univ, Coll Med, Dept Clin Med, Riyadh 13713, Saudi Arabia
关键词
Polypharmacy; Drug-drug interaction; Chronic liver disease; Cirrhosis; Quality of life; BETA-BLOCKERS; CIRRHOSIS; QUESTIONNAIRE;
D O I
10.1016/j.jsps.2023.06.001
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Multiple prescriptions for different medications may be needed for chronic conditions, increasing the risk of polypharmacy. The WHO defined polypharmacy as ''the administration of many drugs at the same time or the administration of an excessive number of drugs". The primary goal of this study was to evaluate polypharmacy in patients with chronic liver disease and to identify potential drug-drug interactions associated with it. A cross-sectional study was conducted at a tertiary care hospital in Mangalore, Karnataka, for six months, from November 2020 to April 2021. The study involved 118 patients with chronic liver disease from various age groups. Data was gathered by analyzing patients' medical records kept on the ward and interviewing them individually. In admission and discharge prescriptions, polypharmacy was examined. Online interaction checkers from Drugs.com and Medscape were used to interpret potential drug-drug interactions. The SF-36 and Chronic Liver Disease Questionnaire were used to measure the quality of life. The data obtained were analyzed statistically to determine the significant correlation. The number of prescribed drugs was significantly correlated (P = 0.018) with the severity of liver disease in Child-Pugh categories B and C. Additionally, moderate polypharmacy reduced quality of life (P < 0.05), and the physical health category was significantly associated with disease severity (P < 0.05). Drug-drug interactions were found in 108 out of the 118 examined prescriptions, totaling 586 interactions in the admission list and 405 interactions in the discharge list. If the potentially serious main drug interaction identified in this study is not well monitored, it could lead to a serious, potentially fatal health condition. Despite being advised, safety is not always guaranteed by liver enzyme monitoring. Therefore, healthcare providers must take additional precautions to avoid inappropriate prescribing, minimize side effects, and ensure drug safety.
引用
收藏
页数:7
相关论文
共 50 条
  • [31] Potential Drug-Drug Interactions in Patients with Coronary Artery Disease
    Secoli, S. R.
    Danzi, N.
    Lorenzi-Filho, G.
    Cesar, L.
    Nunes, F.
    Amaro, A.
    Drager, L.
    Reis, A. M. M.
    DRUG SAFETY, 2008, 31 (10) : 921 - 921
  • [32] Guidelines, polypharmacy, and drug-drug interactions in patients with multimorbidity A cascade of failure
    Marengoni, Alessandra
    Onder, Graziano
    BMJ-BRITISH MEDICAL JOURNAL, 2015, 350
  • [33] Polypharmacy and potential drug-drug interactions in emergency department patients in the Caribbean
    Dookeeram, Darren
    Bidaisee, Satesh
    Paul, Joanne F.
    Nunes, Paula
    Robertson, Paula
    Maharaj, Vidya Ramcharitar
    Sammy, Ian
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACY, 2017, 39 (05) : 1119 - 1127
  • [34] Prevalence of polypharmacy and drug interaction in older adults with rheumatic disease
    Lozano-Lozano, Rodrigo
    Vega-Morales, David
    Sifuentes-Martinez, Macarena del Rosario
    Ornelas-Balcazar, Denisse
    REUMATOLOGIA CLINICA, 2024, 20 (05): : 249 - 253
  • [35] Polypharmacy and severe potential drug-drug interactions among older adults with cardiovascular disease in the United States
    Marwan Sheikh-Taha
    Myriam Asmar
    BMC Geriatrics, 21
  • [36] Polypharmacy and severe potential drug-drug interactions among older adults with cardiovascular disease in the United States
    Sheikh-Taha, Marwan
    Asmar, Myriam
    BMC GERIATRICS, 2021, 21 (01)
  • [37] Drug Administration in Chronic Liver Disease
    Jean-Frédéric Westphal
    Jean-Marie Brogard
    Drug Safety, 1997, 17 : 47 - 73
  • [38] Drug administration in chronic liver disease
    Westphal, JF
    Brogard, JM
    DRUG SAFETY, 1997, 17 (01) : 47 - 73
  • [39] Drug-drug interaction in elderly patients with cancer
    Capitao, Romana
    Jesus, Angelo
    Oliveira, Rita
    Afreixo, Vera
    EUROPEAN JOURNAL OF PUBLIC HEALTH, 2021, 31
  • [40] Drug-Induced Liver Injury in Patients With Chronic Liver Disease
    Ghabril, Marwan
    Vuppalanchi, Raj
    Chalasani, Naga
    LIVER INTERNATIONAL, 2025, 45 (03)